Business Context and Reporting Period
Aquestive Therapeutics, Inc. filed this Form 8-K on September 29, 2026, to report a board appointment. The filing does not report results for a financial reporting period.
Key Event and Governance
- The Board elected Richard J. Daly as a Class I director, effective October 14, 2026. His term is scheduled to expire at the 2028 Annual Meeting of Stockholders.
- The Board determined that Mr. Daly qualifies as an independent director under Nasdaq listing rules. After his appointment, the Board will have eight members, seven of whom are independent.
- The Board approved increasing its size from seven to eight directors, effective October 14, 2026.
- The filing states there are no family relationships with directors or executive officers and no transaction involving Mr. Daly that requires disclosure under Item 404(a) of Regulation S-K.
Director Compensation
Under the Company’s non-employee director compensation program and Equity Grant Policy, Mr. Daly is to receive an initial award of 57,000 stock options under the 2018 Equity Incentive Plan, as amended. The grant is scheduled for the second full trading day after the Company’s next public quarterly or annual earnings release. The exercise price will equal the common stock’s closing market price on the grant date; options vest in annual one-third increments beginning on the first anniversary of that date. The filing does not provide the grant date or exercise price.
Financial Results, Outlook, and Risks
This 8-K contains no revenue, profit, cash flow, margin, debt, liquidity, financial guidance, or operating outlook information. It does not identify a new contingency or unusual financial item.
Important Facts to Verify
- Confirm the effective appointment date of October 14, 2026, and the resulting Board composition.
- Verify the option grant date, exercise price, and final award terms after the next earnings release.
- Review the referenced 2026 proxy statement for the full non-employee director compensation program.